The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2-1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use. J Am Soc Hypertens 2016;10(10):755-762. Ó
Introduction
Neurogenic orthostatic hypotension (nOH) refers to decreased blood pressure (BP) during head-up posture change (ie, standing or head-up tilt) resulting from autonomic failure. Failure of the sympathetic baroreflex results in inadequate norepinephrine release from sympathetic nerves innervating the blood vessels and heart. 1 Autonomic failure occurs in several central and peripheral neurologic disorders, including Parkinson disease (PD), multiple system atrophy (MSA), pure autonomic failure, and peripheral autonomic neuropathy. 1, 2 Estimates suggest that nOH is present in 37% to 58% of patients with PD, 75% of patients with MSA, and 100% of patients with pure autonomic failure. 3 Orthostatic hypotension is associated with significant morbidity and mortality 4 ; patients with nOH have an increased risk of cardiovascular complications as well (eg, heart failure, atrial fibrillation), and many have coexisting cardiovascular comorbidities (eg, hypertension, cardiac, or cerebrovascular conditions). 4, 5 Conflict of interest: S.I. has received compensation from Lundbeck LLC for consulting, speaking, and research activities. S.V. has received personal compensation from Lundbeck for advisory board and speaker bureau activities, consulting fees from Athena Diagnostics (Quest), and compensation as an associate editor of JAMA Neurology. U.K. is an employee of Lundbeck, which funded this study; A.Z. and G.J.R. were Lundbeck employees at the time of contribution. W.B.W. is a safety consultant for Lundbeck LLC. No author received compensation for preparation or writing of this manuscript.
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Droxidopa is an oral norepinephrine prodrug approved in the United States for the treatment of symptomatic nOH in patients with primary autonomic failure (PD, MSA, pure autonomic failure), dopamine b-hydroxylase deficiency, or nondiabetic autonomic neuropathy (NDAN). 6 In shortterm phase 3 trials, droxidopa significantly improved the hallmark symptoms of nOH (eg, orthostatic dizziness, lightheadedness, or the ''feeling like you are about to black out''), with patients reporting improved symptom severity and impact on daily activities compared with placebo. [7] [8] [9] Droxidopa also increased standing systolic BP (SBP) in these patients. 9 ,10 Short-term treatment with droxidopa was well tolerated in these studies, and most adverse events (AEs) were mild or moderate in severity. [7] [8] [9] The incidence of supine hypertension, defined as SBP >180 mm Hg, ranged from 5% to 14%. Rates of other cardiovascular events were low (eg, coronary artery disease, hypertension [0%-8%]).
Previous trials evaluated the efficacy and safety of droxidopa over relatively short treatment durations of 1-2 and 8-10 weeks. [7] [8] [9] The objective of the present study was to evaluate the long-term safety of droxidopa for the treatment of symptomatic nOH based on frequency and type of AEs, BP and heart rate, and laboratory findings.
Methods
This was a phase 3, multinational, multicenter, openlabel study in ambulatory patients with symptomatic nOH that assessed the long-term safety of droxidopa (ClinicalTrials.gov identifier, NCT01132326). Patients entering this long-term study were required to have participated in a prior short-term, 9 8-to 10-week, 8, 10 or 1-year 11, 12 
Patients
Eligible patients were 18 years of age with symptomatic nOH (defined as a 20-mm Hg reduction in SBP on standing) associated with PD, MSA, pure autonomic failure, or NDAN. Key exclusion criteria included use of vasoconstricting agents or long-acting antihypertensive medications, uncontrolled cardiac arrhythmias, a history of myocardial infarction within the past 2 years, current unstable angina, uncompensated congestive heart failure (New York Heart Association Class III or IV), or diabetic autonomic neuropathy. Patients with sustained severe hypertension (defined as SBP 180 mm Hg or diastolic BP [DBP] 110 mm Hg) were also excluded. To assess for the presence of severe hypertension, BP was measured in a supine (ie, semirecumbent; head and torso elevated approximately 30-degrees from horizontal) or seated position at three consecutive measurements within 1 hour.
Treatments
Droxidopa was administered at doses of 100 to 600 mg in 100-mg increments taken three times daily (TID); doses were taken upon waking and at approximately 4-hour intervals to allow the last dose to be taken in the late afternoon and early enough before bedtime to minimize the risk of hypertension during sleep (ie, supine hypertension). Patients received individualized doses that had been identified during the titration period of a previous study, with some exceptions: all patients who entered the present study from the 8-to 10-week double-blind study underwent dose titration in the present study. At the discretion of the treating investigator physician, droxidopa doses could be adjusted up or down in single steps for efficacy or safety. Dose escalation was stopped if the patient had sustained SBP >180 mm Hg or DBP >110 mm Hg in the supine (or semirecumbent) position was unable to tolerate side effects believed to be related to the study drug or reached the maximum dose of droxidopa (600 mg TID; 1800 mg/d).
Scheduled assessments were conducted at months 1 and 3, and every 3 months thereafter. Vasoconstricting agents (eg, ephedrine, dihydroergotamine, midodrine), tryptaminebased drugs (triptans; eg, sumatriptan), cyclopropane or halogen-containing inhalational anesthetics (eg, halothane), catecholamine-containing preparations (eg, isoproterenol [isoprenaline]), nonselective monoamine oxidase inhibitors, long-acting antihypertensives, and ergotamine derivatives (except medications for PD) were prohibited during the study. Fludrocortisone was permitted, as were all PD drugs.
Assessments
AEs, vital signs, and laboratory testing results were recorded at each clinic visit. Investigators classified AEs by severity after obtaining the patient's medical history. Laboratory testing included hematology, chemistry, and urinalysis; women of childbearing potential underwent a pregnancy test at each study visit. Vital sign assessment included BP (measured using the same calibrated equipment at each visit), heart rate, temperature, and weight.
Data Analyses
All patients who received at least 1 dose of droxidopa were evaluated for safety. Continuous variables were summarized descriptively; frequencies and percentages were calculated for categorical variables. In comparisons with baseline, baseline values reflect evaluations performed before the first dose of study treatment in a short-term, double-blind study unless the last visit in these studies occurred >1 month before the start of the present study; all patients were off study drug at the time of baseline evaluations.
Results

Patients and Treatment
A total of 350 patients, enrolled at 111 centers in 7 countries, were included in the safety analysis. The mean age was 66 years, and most patients were men and white (Table 1) . Levodopa and dopa decarboxylase inhibitors (carbidopa or benserazide combinations), with or without catechol-O-methyl transferase inhibitors (entacapone), were used by 66.9% of patients (n ¼ 234/350; Table 2 ). Monoamine oxidase B inhibitors or dopamine agonists were used by 24.9% (n ¼ 87/350) and 22.3% (n ¼ 78/ 350) of patients, respectively. Fludrocortisone or fludrocortisone acetate was used by 33.7% patients. Short-acting antihypertensives of various drug classes were used by 0.3%-4.0% of the study population. The most common reason for noncompletion of the study (36.7% of the total population) was the transition of patients to a compassionate-use access program; this program was available to patients at non-US sites after the study was terminated in the European Union and Canada. Other reasons for study discontinuation included withdrawal of consent (18.8%), AEs (17.0%), and lack of efficacy (11.5%; Figure 1 ).
The mean duration of exposure to droxidopa during the study was 362.6 days (median, 265 days; range, 2 to 1133 days). The mean prescribed daily dose was 419.8 mg TID (median, 409.1 mg TID). The most commonly administered dose of droxidopa was 600 mg TID (42.3%, n ¼ 148/350), while 14.3%, 16.9%, and 15.7% of patients received 300, 400, or 500 mg TID, respectively.
Safety
AEs were reported by 75.1% of patients (n ¼ 263/350; Table 3 ). The most frequently reported AEs were falls (23.4%), urinary tract infection (13.4%), headache (12.0%), syncope (12.0%), and dizziness (9.7%). The majority (92.3%) of AEs were mild or moderate in severity, and most of the common AEs (ie, falls, urinary tract infection, and syncope) were reported by investigator physicians to be manifestations of the underlying diseases (nOH, PD, SD, standard deviation. * Long-term, open-label study baseline values reflect evaluations performed before the first dose of study treatment in a short-term, double-blind study unless the last visit in these studies occurred >1 month before the start of the present study; all patients were off study drug at the time of baseline evaluations. be related to the underlying neurogenic diseases. The most common SAEs were syncope (2.9%), pneumonia (2.0%), and dehydration (2.0%). The rates of SAEs were highest in patients with a primary diagnosis of MSA (45.5%) compared with those with PD (25.0%) or pure autonomic failure (8.8%). There were 35 discontinuations due to SAEs. Nineteen patients (5.4%) reported 25 cardiac-related AEs; 10 events were mild, 9 were moderate, and 6 were severe. The severe cardiac-related AEs included atrial fibrillation (n ¼ 1), cardiorespiratory arrest (n ¼ 2), myocardial infarction (n ¼ 2), and cardiac arrest (n ¼ 1). Cardiac-related AEs reported by >1 patient were atrial fibrillation (5 patients [1.4%]) and atrial flutter, bradycardia, cardiorespiratory arrest, myocardial infarction, and palpitations (2 patients [0.6%] each). Eleven cardiacrelated AEs were considered SAEs. The patient who experienced atrial flutter had a medical history of atrial fibrillation.
There were 20 deaths during the study (Table 5 ). Nearly half of these deaths (n ¼ 9/20; 45.0%) occurred in patients with a diagnosis of MSA, and 60.0% of deaths (n ¼ 12/20) were associated with progression of disease, respiratory failure, or infection. The cause of one death was unknown. The remaining deaths (n ¼ 7/20; 35.0%) were reported to have cardiovascular causes. Three patients with fatal cardiovascular SAEs had a medical history of cardiovascular conditions. One fatal SAE (myocardial infarction) occurred in a 62-year-old patient with pure autonomic failure after approximately 18 months of treatment. This patient had a history of myocardial infarction, coronary artery disease, and angina (all >2 years before study entry), and the SAE was assessed by the investigator as not related to study drug ( Table 5 ). The duration of exposure to droxidopa in the present study at the time of the fatal events ranged from 37 to 777 days (median, 439 days). There was no clustering of fatal events around the initiation of droxidopa. Two fatal events (pneumonia and myocardial infarction) were designated by local site investigators as possibly related to droxidopa.
Vital Signs
Blood Pressure SBP and DBP were recorded at each study visit in the seated or supine (ie, semirecumbent) position. At baseline, the mean (SD) SBP was 122 (23.5) mm Hg and the mean (SD) DBP was 72 (11.9) mm Hg. Generally, mean changes from baseline in both SBP and DBP were small at most time points (Figure 2 ). There were 17 patients (4.9%) with 21 AEs of hypertension, and 7 patients (2.0%) with 8 reported instances of increased BP. The rates of SBPs >180 mm Hg ranged from 0.6% (month 3) to 2.3% (month 24). No patient had a DBP >120 mm Hg during the study.
Heart Rate
At baseline, the mean (SD) heart rate was 71 (10.1) beats/min. Mean changes from baseline in heart rate at months 12, 18, and 24 were 1 (9.8), 3 (11.5) bpm, and 0 (8.9) beats/min, respectively.
Laboratory Findings
Laboratory values showed no trends or consistent changes from baseline that were considered to be clinically significant. Fifty-two patients (14.9%) had a total of 158 AEs related to abnormal laboratory parameters. The most frequently reported laboratory-related AEs were decreased weight (3.4%), increased blood creatinine (3.1%), white blood cells in urine (2.3%), increased blood creatine phosphokinase (2.0%), and increased blood urea (2.0%). Except for one severe AE of hypoglycemia that occurred in a patient with diabetes using insulin, all AEs related to abnormal laboratory parameters were considered mild or moderate in severity by the investigators.
Discussion
Previous studies of the synthetic norepinephrine prodrug droxidopa in patients with symptomatic nOH have demonstrated the drug to be effective and well tolerated in short-term clinical trials. The present study extends our knowledge of the safety of long-term use of droxidopa to treat patients with symptomatic nOH secondary to autonomic failure in PD, pure autonomic failure, MSA, and NDAN. Only 7% of the study population discontinued because of a lack of efficacy, suggesting durability of efficacy of droxidopa in these patients.
There were 20 deaths over the course of this study (5.7%), 7 of which were related to cardiovascular AEs (carotid artery thrombosis [ 
, and cardiac arrest [n ¼ 1]). Although patients with nOH are at increased risk of cardiovascular complications, 5 the incidence of cardiovascular AEs was relatively low (5.4%) in this study. Many patients with primary autonomic failure have both orthostatic hypotension and supine hypertension, which can be exacerbated by medications used to treat orthostatic hypotension. 13, 14 In this study, however, AEs of hypertension and increased BP, measured in a seated or supine (ie, semirecumbent) position, were reported for 4.9% and 2.0% of patients, respectively. When compared with rates of cardiac AEs in reports of shortterm clinical trials, 7-9 the risk of cardiac AEs did not appear to increase with longer exposure to droxidopa, and long-term droxidopa did not appear to be associated with an increased risk of cardiac AEs in this population. However, the enrollment criteria excluded patients with severe cardiovascular disease, and those with cardiovascular disease represented only a minority of patients that continued into this long-term study. Thus, it is difficult to generalize these safety results to patients with preexisting cardiovascular disorders. Furthermore, the study population included a small number of patients with NDAN (n ¼ 8) and no patients with dopamine b-hydroxylase deficiency, which limits conclusions that can be drawn about droxidopa cardiovascular safety in patients with nOH associated with these diagnoses.
In the current long-term droxidopa treatment study, no new safety concerns were identified, and safety results were similar to those observed in short-term phase 3 efficacy studies. [7] [8] [9] In two previous trials, AEs were reported by 58.6% and 82.0% of patients, 7, 8 with lower rates observed during the open-label dose-escalation and double-blind treatment phases of a third trial (38.0% and 18.5%, respectively). 9 Discontinuation due to an AE was reported for 4.9% to 12.4% of patients. [7] [8] [9] As expected, overall rates of AEs and discontinuations due to AEs were higher (75.1% and 13.4%, respectively) in the current study given the longer duration of follow-up compared with the short-term trials (362.6 days vs. 1-2 and 8-10 weeks). A high discontinuation rate introduced the possibility of retention bias and is a major limitation of this study. The discontinuation rate may have been influenced by patients' overall health status. Many patients in this trial had a progressive neurodegenerative disorder that increased the risk of developing a comorbid health condition over time. 4, 5 A limitation of this analysis is confounding by the openlabel nature of the study design. Although all patients included this open-label extension study entered from earlier double-blind, placebo-controlled trials of droxidopa, the potential for bias associated with the open-label trial design includes patient recruitment or retention issues (eg, patients may be more likely to continue in an openlabel trial because receipt of active treatment is assured, and the studies usually entail less complex treatment regimens and study assessment schedules than a double-blind study), psychological effects (from knowledge of treatment assignment), and AEs reporting (due to patient/investigator awareness). 15, 16 However, an open-label study can complement results identified in double-blind trials 15 and may be considered a relevant indicator of treatment effects consistent with those that would be observed in normal clinical practice. 16 In conclusion, droxidopa was well tolerated during longterm use in this long-term, open-label study in patients with symptomatic nOH associated with PD, MSA, pure autonomic failure, or NDAN. Most AEs, including cardiac AEs, were mild or moderate in severity; long-term use of droxidopa did not appear to be associated with increased risk of cardiovascular-related AEs or increased incidence of laboratory abnormalities.
